Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation

Background: The treatment of multiple myeloma (MM) has evolved significantly in the past decade, and new drug combinations have improved the response rates and prolonged survival. Studies comparing different induction chemotherapy regimens have shown that triple combinations have better results than...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Edvan De Queiroz Crusoe, Fabiana Higashi, Gracia Martinez, Rosane Bittencourt, Jorge Vaz Pinto Neto, Lais Sousa, Rodrigo Santucci, Roberto José Pessoa Magalhães, Gilberto Colli, Renata Ferreira Marques Nunes, Glaciano Ribeiro, Jandir Nicacio, Karla Richter Zanella, Jose Mauro Kutner, Andre Magalhaes, Danielle Leao, Abrahão Elias Hallack Neto, Walter Braga, Emanuella G Souza, Antonio Julio A.M. Guimaraes, Giovanna Steffenello Durigon, Dani Laks, Angelo Maiolino, Vania Tietsche de Moraes Hungria
Format:	Artigo
Język:	Inglês
Wydane:	Elsevier 2020-04-01
Seria:	Hematology, Transfusion and Cell Therapy
Hasła przedmiotowe:	Antineoplastic combined chemotherapy protocols Bone marrow transplantation Bortezomib Multiple myeloma Thalidomide
Dostęp online:	http://www.sciencedirect.com/science/article/pii/S253113791930118X
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!